Evidence map›Paper›PMID 31677037›Full record

ArticleMolecular biology reports2020

Isoquercetin regulates SREBP-1C via AMPK pathway in skeletal muscle to exert antihyperlipidemic and anti-inflammatory effects in STZ induced diabetic rats.

Muthukumaran Jayachandran, Tongze Zhang, Ziyuan Wu, Yinhua Liu, Baojun Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Therapeutic potential ofFrontiers in pharmacology · 2025
    Review
  3. Phytochemical Composition ofAdvances in pharmacological and pharmaceutical sciences · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Muthukumaran JayachandranFood Science and Technology Program, Beijing Normal University-Hong Kong Baptist University United International College, 2000, Jintong Road, Tangjiawan, Zhuhai, 519087, Guangdong, China.
Tongze ZhangFood Science and Technology Program, Beijing Normal University-Hong Kong Baptist University United International College, 2000, Jintong Road, Tangjiawan, Zhuhai, 519087, Guangdong, China.
Ziyuan WuFood Science and Technology Program, Beijing Normal University-Hong Kong Baptist University United International College, 2000, Jintong Road, Tangjiawan, Zhuhai, 519087, Guangdong, China.
Yinhua LiuBiomedicine Research and Development Center, Zhuhai Campus of the Zunyi Medical University, Zhuhai, 519041, Guangdong, China.
Baojun XuFood Science and Technology Program, Beijing Normal University-Hong Kong Baptist University United International College, 2000, Jintong Road, Tangjiawan, Zhuhai, 519087, Guangdong, China. baojunxu@uic.edu.hk.ORCID http://orcid.org/0000-0003-0739-3735
Beijing Normal-Hong Kong Baptist University · CNZunyi Medical University · CN

Funding

BNU-HKB United International College R201914
6 · The paper itself

Abstract

Diabetes mellitus (DM) is a cluster of metabolic diseases that exhibits high blood glucose levels accompanied by hyperlipidemia and inflammation. DM is the primary risk factor contributes majorly to cardiovascular disease (CVD) mediated morbidity and mortality. The incidence of dyslipidemia seems to attribute considerably to the initiation of CVDs. The beneficial action of isoquercetin on hyperlipidemia and related signaling pathways are not documented yet, hence we decide to carry out this study. The experimental rats were divided into five groups: Group 1, control rats; group 2, isoquercetin control (40 mg/kg b.w); group 3, diabetic rats (STZ-40 mg/kg b.w); group 4, diabetic + isoquercetin (40 mg/kg b.w); and group 5, diabetic + glibenclamide (600 µg/kg b.w). The animals were sacrificed at the end of the experimental duration of 45 days. Results of our analysis reveal that isoquercetin have a major impact on the tissue lipid profile, isoquercetin strongly regulates the expression of various lipid-metabolizing enzymes, C-reactive protein, expression of various inflammatory genes, SREBP-1C genes and proteins and AMP-activated protein kinase-α (AMPK) signaling pathway genes and proteins. Results recommend that isoquercetin can be effective in mitigating the consequences of hyperlipidemia and DM.

Indexed as

Acyl Coenzyme AAMP-Activated Protein KinasesAnimalsAnti-Inflammatory AgentsDiabetes Mellitus, ExperimentalHypolipidemic AgentsLipid MetabolismMaleMuscle, SkeletalQuercetinRatsRats, WistarSignal TransductionSterol Regulatory Element Binding Protein 13-hydroxy-3-methylglutaryl-coenzyme AAcyl Coenzyme AAMP-Activated Protein KinasesAnti-Inflammatory AgentsHypolipidemic AgentsisoquercitrinQuercetinSrebf1 protein, ratSterol Regulatory Element Binding Protein 1AMPK-αHMG-Co-AHyperlipidemiaSREBP-1CStreptozotocin

Identifiers

PMID31677037
OpenAlexW2986127397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.